What is the Function of Glucose Attached to Hemoglobin?
Glucose attached to hemoglobin (HbA1c) has no physiological function—it is simply a biochemical marker that reflects average blood glucose levels over the preceding 2-3 months. The glycation of hemoglobin is a passive, non-enzymatic process that occurs as a byproduct of glucose exposure, not a functional modification that serves any biological purpose 1.
How Glycated Hemoglobin Forms
The attachment of glucose to hemoglobin occurs through a non-enzymatic posttranslational modification where glucose spontaneously condenses with the free amine group on the N-terminal valine residues of the hemoglobin β-chain 1. This process unfolds in two steps:
- Initial binding: Glucose forms an unstable Schiff base with hemoglobin
- Amadori rearrangement: The Schiff base undergoes an irreversible rearrangement to form a stable ketoamine structure 1
Glycation also occurs at certain lysine residues on both the α- and β-chains of hemoglobin 1.
Clinical Utility as a Biomarker
While glycated hemoglobin serves no biological function, it has become the gold standard clinical tool for assessing long-term glycemic control in diabetes management 1. Its utility stems from the direct relationship between HbA1c levels and mean blood glucose:
- Erythrocytes are continuously glycated during their 120-day lifespan
- The rate of glycohemoglobin formation is directly proportional to ambient glucose concentration 1
- In the Diabetes Control and Complications Trial, each 1% increase in HbA1c corresponded to approximately a 35 mg/dL (2 mmol/L) increase in mean plasma glucose 1
Time-Weighted Reflection of Glycemia
HbA1c does not equally reflect glucose levels across the entire 120-day red blood cell lifespan. Recent glycemic control is overrepresented 1:
- 50% of HbA1c is determined by glycemia during the 1 month preceding measurement
- 25% from 30-60 days before measurement
- 25% from 60-120 days prior to measurement
Structural and Functional Consequences
Although glycation serves no physiological purpose, it does cause detrimental structural changes to hemoglobin that can compromise its oxygen transport function 2:
- The T-state (low-affinity conformation) of HbA1c is destabilized compared to native hemoglobin 3
- The Bohr effect is reduced 3
- Binding affinity for 2,3-diphosphoglycerate (DPG) is altered—the T-state affinity is 2.6× lower than native hemoglobin 3
- The sugar moieties are asymmetrically disposed within the DPG binding site, changing the internal geometry 3
In hyperglycemic states, excessive glycation can lead to amyloid aggregate formation, which is strongly associated with diabetic complications and neurodegenerative diseases 2.
Important Clinical Caveats
Several conditions can falsely alter HbA1c measurements independent of actual glycemic control 1:
Conditions that falsely lower HbA1c:
- Any process shortening erythrocyte lifespan (hemolytic anemia, blood loss recovery, hemoglobinopathies)
- Kidney disease
- Liver disease
- Vitamins C and E supplementation (may inhibit glycation) 1
Conditions that falsely elevate HbA1c:
- Hemoglobin variants (S, C, and over 700 other variants can cause spurious results through assay interference) 1
- Chemically modified hemoglobin (carbamylated hemoglobin in uremia, acetylated hemoglobin from high-dose salicylates) 1
When HbA1c results are surprisingly high, low, or change significantly with a laboratory method change, suspect a hemoglobin variant and consider using boronate affinity chromatography methods 1.
Despite these potential confounders, HbA1c remains the optimal test for monitoring glucose control even in populations with high prevalence of conditions that may affect its reliability 4.